On May 15, 2025 SparX Biopharmaceutical Corp ("SparX"), a clinical-stage biotechnology company pioneering next-generation antibody-drug conjugate (ADC) technologies, reported the signing of a research agreement with Mitsubishi Tanabe Pharma America, Inc. (MTPA) (Press release, Sparx Therapeutics, MAY 15, 2025, View Source [SID1234653195]). This collaboration aims to advance an innovative ADC program: a conceptually novel immune cell target-based ADC.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The research with MTPA will focus on an ADC against a first-in-class immune cell target, with the potential to serve as a universal tumor-targeting strategy across multiple cancer types.

"This collaboration marks significant milestone for SparX, reflecting the strength of our novel target discovery capabilities" said Gui-Dong Zhu, Ph.D., Founder and CEO of SparX Biopharmaceutical Corp. "We are excited to work alongside MTPA to bring transformative ADC therapies to patients worldwide."